Discounted Cash Flow (DCF) Analysis Unlevered

NOXXON Pharma N.V. (ALNOX.PA)

0.041 €

0.00 (0.00%)
All numbers are in Millions, Currency in USD
Stock DCF: - | 0.041 | undervalue

Operating Data

Year
A/P
2017
Projected
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue ----------
Revenue (%)
EBITDA ----------
EBITDA (%)
EBIT ----------
EBIT (%)
Depreciation ----------
Depreciation (%)

Balance Sheet Data

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Total Cash ----------
Total Cash (%)
Account Receivables ----------
Account Receivables (%)
Inventories ----------
Inventories (%)
Accounts Payable ----------
Accounts Payable (%)
Capital Expenditure ----------
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 0.041
Beta 2.238
Diluted Shares Outstanding 0.31
Cost of Debt
Tax Rate 0.00
After-tax Cost of Debt 61.64%
Risk-Free Rate
Market Risk Premium
Cost of Equity 14.298
Total Debt 2.44
Total Equity 0.01
Total Capital 2.45
Debt Weighting 99.47
Equity Weighting 0.53
Wacc

Build Up Free Cash

Year
A/P
2017
Projected
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue ----------
EBITDA ----------
EBIT ----------
Tax Rate 0.07%0.03%-0.12%0.01%0.00%-0.00%-0.00%-0.00%-0.00%-0.00%
EBIAT ----------
Depreciation ----------
Accounts Receivable ----------
Inventories ----------
Accounts Payable ----------
Capital Expenditure -0-0.01-0.02-0.04-0.01-----
UFCF ----------
WACC
PV UFCF ----------
SUM PV UFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 61.39
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -7.02
Equity Value -
Shares Outstanding 0.31
Equity Value Per Share -